At EuroPCR 2023, Drs Christopher Meduri, Susheel Kodali, and João Cavalcante discuss the changing TAVR landscape and the early safety and feasibility of a first new class of biomimetic transcatheter aortic valve – DurAVR® Transcatheter Heart Valve (THV).

Learn about:

• Why hemodynamics matter in TAVR.
• The needs of younger TAVR patients and current treatment challenges.
• The implications of abnormal flow vs. laminar flow post-TAVR.
• The biomimetic design of DurAVR® THV and how it’s different from bioprosthetic valves.
• Hemodynamic results from the DurAVR® THV First-in-Human study.
• Flow dynamics results from the DurAVR® THV First-in-Human study on 2D cardiac MRI compared to other valves and a healthy aortic valve.